LABP — Landos Biopharma Cashflow Statement
0.000.00%
Last trade - 00:00- $69.71m
- $40.70m
- 20
- 12
- 93
- 37
Annual cashflow statement for Landos Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -13.5 | -30.1 | -38.4 | -39.3 | -21.9 |
| Depreciation | |||||
| Non-Cash Items | 0.213 | 1.17 | 5.27 | 3 | 1.01 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 3.28 | 5.87 | 5.89 | -10.1 | 0.443 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -9.87 | -23 | -27.1 | -45.8 | -20.5 |
| Capital Expenditures | -0.158 | -0.181 | -0.44 | -0.007 | 0 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -40.2 | 14.3 | -58.3 | 74.1 | 7.78 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -40.3 | 14.1 | -58.7 | 74.1 | 7.78 |
| Financing Cash Flow Items | — | — | -1.91 | 0 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 59.6 | 1.52 | 91.6 | 0 | 13.6 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 9.45 | -7.39 | 5.89 | 28.3 | 0.909 |